PT - JOURNAL ARTICLE AU - Gordon, Debra ED - Pratley, Richard TI - Recent Data from LEAD DP - 2010 Dec 01 TA - MD Conference Express PG - 18--19 VI - 10 IP - 9 4099 - http://mdc.sagepub.com/content/10/9/18.short 4100 - http://mdc.sagepub.com/content/10/9/18.full AB - In patients with diabetes, vascular conditions are responsible for the majority of morbidity, mortality, and cost that are attributed to the disease [Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007]. The Liraglutide Effect and Action in Diabetes [LEAD; NCT00700817] trials are designed to evaluate the efficacy and safety of glucagon-like peptide-1 agonist compared with existing antidiabetic therapies.